Mycobacterium avium complex (MAC) lung disease in two inner city community hospitals: Recognition, prevalence, co-infection with mycobacterium tuberculosis (MTB) and pulmonary function (PF) improvements after treatment

Open Respiratory Medicine Journal

Volumn 4, Issue , 2010, Pages 76-81

  Khan, Zinobia ^a   Miller, Albert ^a   Bachan, Moses ^a   Donath, Joseph ^a  

^a Mary Immaculate Hospital   (United States)

Author keywords

Bacillus Calmette Guerin (BCG) vaccination; Bronchiectasis; Bronchoalveolar lavage (BAL); Cavitation; Immunocompetent; Mycobacterium avium complex (MAC); Mycobacterium tuberculosis (MTB); Non Tuberculous mycobacteria (NTM); Pulmonary function (PF)

Indexed keywords

BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; ATYPICAL MYCOBACTERIUM; CLINICAL ARTICLE; COMMUNITY HOSPITAL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; IMMUNOCOMPROMISED PATIENT; LUNG FUNCTION; LUNG LAVAGE; LUNG VOLUME; MALE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SMOKING; SPIROMETRY; SPUTUM CULTURE;

EID: 84987711675     PISSN: None     EISSN: 18743064     Source Type: Journal    
DOI: 10.2174/1874306401004010076     Document Type: Article

References (12)

1. Eaton T, Fakinham JO III, Von Reyn CF. Recovery of Mycobacterium avium from Cigarettes. J Clin Microbiol 1995; 33: 2757-58.
2. Field S, Cowie R. Lung disease due to the more common non tuberculous Mycobacteria. Chest 2006; 129: 1653-72.
3. Crow HE, King CT, Smith CE, et al. A limited clinical, pathological and epidemiologic study of patients with pulmonary lesions associated with atypical acid – fast bacilli in the sputum. Am Rev Respir Dis 1957; 75: 199-222.
4. Prince DS, Peterson DD, Steiner RM, et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321: 863-68.
5. Beck F. Pulmonary disease due to atypical tubercle bacilli. Am Rev Respir Dis 1959; 80: 738-43.
6. Warring Fc Jr. Mycobacteria in a New England hospital: a study of mycobacterial species occurring in the sputum of patients with chronic pulmonary disease. Am Rev Respir Dis 1968; 98: 965-77.
7. American Thoracic Society. Diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am J Respir Crit Care Med 2007; 175: 367-416.
8. Miller A, Thornton JC, Warsaw R, Bernstein J, Teirstein AS, Selikoff IJ. Mean and instantaneous expiratory flows, FVC and FEV1: prediction equations for non-smokers and smokers from a random sample of Michigan, a large industrial state. Bull Physiopath Respir 1986; 22: 589-97.
9. Miller A, Thornton JC, Warshaw R, Anderson H, Teistein AS, Selikoff IJ. Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state: predicted values, lower limits of normal, and frequencies of abnormality by smoking history. Am Rev Respir Dis 1983; 127: 270-7.
10. Billinger ME, Olivier KN, Viboud C, et al. Nontuberculous Mycobacteria–associatedl lung disease, in hospitalized persons, United States, 1998-2005. Emerg Infect Dis 2009; 15(10): 1562-9.
11. Trnka L, Dankova D, Svandova E. Six years experience with the discontinuation of BCG vaccination: Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex. Tuberc Lung Dis 1994; 75: 348-52.
12. O’Brien DP, Currie BJ, Krause VL, et al. Non-tuberculous mycobacterial disease in Northern Australia: a case series and review of the literature. Clin Infect Dis 2000; 31: 958-68.